NIH-Funded Team Discovers Miniaturized CRISPR Enzyme Al3Cas12f, Enabling Precision In Vivo Gene Delivery via AAV Vectors

July 19, 2026

National Institutes of Health (NIH) USA

Overview

An NIH-funded research team has discovered a novel, enhanced miniaturized CRISPR gene-editing system, a natural enzyme named ‘Al3Cas12f,’ capable of targeted in vivo delivery. This enzyme is notably small enough to be efficiently packaged into adeno-associated virus (AAV) vectors, a primary delivery method for gene therapy. This breakthrough addresses one of the major limitations of CRISPR technology—efficient in vivo delivery—and is expected to have broad applications in future precision gene therapies, significantly improving the feasibility of gene therapies for a wider range of diseases.

In Depth

Key Findings

On July 15, 2026, a research team funded by the U.S. National Institutes of Health (NIH) announced the discovery of a groundbreaking miniaturized CRISPR gene-editing enzyme, ‘Al3Cas12f,’ capable of enabling targeted in vivo gene delivery. The most significant feature of this naturally occurring enzyme is its compact size, which allows for efficient packaging into adeno-associated virus (AAV) vectors, the most widely used delivery method in gene therapy.

Technical / Clinical Details

While CRISPR-Cas systems have revolutionized gene therapy with their ability to precisely cut and edit specific DNA sequences, a major challenge to their practical application has been the efficient delivery of Cas proteins into cells, particularly to target tissues within the body. Many Cas enzymes are large, exceeding the packaging capacity of versatile viral vectors like AAV. Al3Cas12f overcomes this challenge by combining a small size (approximately half that of conventional Cas9) with efficient DNA cleavage activity. Its ability to be packaged into AAV vectors enables safe and effective delivery of gene-editing tools to various tissues, including the brain, liver, and muscle. This advancement makes previously difficult in vivo gene therapy approaches much more feasible.

Background & Context

In vivo gene therapy is highly anticipated as a less invasive and more convenient treatment option, eliminating the need for ex vivo cell manipulation. However, in vivo delivery of CRISPR systems has faced technical barriers such as viral vector size limitations, immunogenicity, and off-target effects. The discovery of Al3Cas12f opens a crucial pathway to maximize the payload capacity of viral vectors and accommodate more gene therapy candidates for AAV packaging while maintaining target specificity. This is a critical breakthrough for accelerating gene therapy development, especially for hereditary and chronic diseases.

Strategic Significance & Outlook

The discovery of the Al3Cas12f enzyme significantly advances the clinical application of CRISPR-based gene therapies. Moving forward, preclinical and clinical studies evaluating the safety and efficacy of in vivo gene therapy using this miniaturized CRISPR system are expected to accelerate. Al3Cas12f presents new possibilities, especially for treating large genes that were previously challenging to deliver due to AAV payload limits, and for diseases requiring simultaneous editing of multiple genes. This technology is poised to revolutionize therapeutic development across a broad spectrum of diseases, including genetic disorders, cancer, and infectious diseases, paving the way for a future of safer and more effective gene therapy options for patients.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.